descriptive
Analysis v1
Strong Support
A new antifungal medicine called rezafungin was approved by the FDA in 2023 for treating serious yeast infections in adults who don't have many other treatment options.
1
0
Evidence from Studies
Supporting (1)
1
Community contributions welcome
1
FDA-Approved Antibacterials and Echinocandins
Narrative Review
2025 Feb 7The study confirms that the FDA approved an echinocandin peptide drug in 2023, which matches the claim about rezafungin. However, it's a general review and doesn't specifically name rezafungin or verify its exact use for treating candidemia and invasive candidiasis.
Contradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.